Delving into the Latest Updates on Virostatics Srl with Synapse

Overview

Tags

Infectious Diseases

Urogenital Diseases

Respiratory Diseases

Chemical drugs

Therapeutic vaccine

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	6
Immune System Diseases	2
Neoplasms	1

Top 5 Drug Type	Count

Chemical drugs	5
Therapeutic vaccine	1
Small molecule drug	1
DNA vaccine	1

Top 5 Target	Count

CDK6(Cyclin-dependent kinase 6)	1
CDK9(Cyclin-dependent kinase 9)	1

Antiretroviral-Sparing Concept: An Exploratory Phase II, Randomized, Single Blind Placebo-Controlled Study to Investigate the Effect of Therapeutic Immunization on the Quantity of HIV-Specific T Cell Precursors During Highly Active Antiretroviral Therapy Followed by Analytical Treatment Interruption

PHPC-02 is a phase II, randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load set point following analytical treatment interruption (ATI). Subjects will be randomized to receive either DermaVir Patch (8 subjects per cohort) or DermaVir Patch Placebo (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks.

Start Date01 Apr 2009

Sponsor / Collaborator

Genetic Immunity, Inc.

[+1]

EUCTR2008-006912-39-IT / Not yet recruitingNot Applicable

ANTIRETROVIRAL-SPARING CONCEPT: AN EXPLORATORY PHASE II, RANDOMIZED, SINGLE BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF THERAPEUTIC IMMUNIZATION ON THE QUANTITY OF HIV-SPECIFIC T CELL PRECURSORS DURING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY FOLLOWED BY ANALYTICAL TREATMENT INTERRUPTION - ND

Start Date26 Jan 2009

Sponsor / Collaborator

Virostatics Srl

EUCTR2007-002460-98-IT / Not yet recruitingNot Applicable

A randomized double-blind dose-finding multi-centre phase IIa study with VS411 for HIV-1 infection. - ND

Start Date07 Feb 2008

Sponsor / Collaborator

Virostatics Srl

100 Clinical Results associated with Virostatics Srl

Login to view more data

0 Patents (Medical) associated with Virostatics Srl

Login to view more data

2

Literatures (Medical) associated with Virostatics Srl

28 Nov 2012·Frontiers in Medicinal Chemistry

AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs): A New Class of Antiviral Drugs

Author: Stevens, Mike ; De Forni, Davide ; Lisziewicz, Julianna ; Lori, Franco

This paper will review recent discoveries in the field of viral pathogenesis and the development of a new antiretroviral class known as AntiViral-HyperActivation Limiting Therapeutics^# (AV-HALTs) that has been specifically designed in response to these findings.AV-HALTs are characterized by the combination of two distinct activities - the direct inhibition of viral replication (antiviral activity) and the reduction of excessive chronic immune system hyperactivation (hyperactivation limiting effect).These two effects can be achieved by combining two drugs (a first-generation AV-HALT) or by a single mol. (second-generation AV-HALTs).The medical need for AV-HALTs is best illustrated in the treatment of the Human ImmunoDeficiency Virus Type 1 (HIV-1).Paradoxically, it is the chronic, excessive hyperactivation of the immune system, resulting in cellular hyperproliferation and systemic inflammation - throughout the course of HIV disease - that is now recognized as the major driver of not only the continual loss of CD4⁺ T cells and progression to the Acquired Immunodeficiency Syndrome (AIDS), but also of the emergence of both AIDS-defining and non-AIDS-defining events that neg. impact upon both morbidity and mortality despite otherwise successful (ie, fully virus suppressive) HIV therapy.This review will focus upon the establishment of the human proof of concept for AV-HALTs using a two-drug, first-generation AV-HALT (VS411) and the development of single-mol., second-generation AV-HALTs for the treatment of HIV-1 disease and other chronic viral infections.

Transistors platform for rapid and parallel detection of multiple pathogens by nanoscale-localized multiplexed biological activation

Author: Weck, Marcus ; Nasralla, Hashem ; Li, Yanxiao ; de Peppo, Giuseppe ; Riedo, Elisa ; de Forni, Davide ; Patera, Andrew ; Hannigan, Matthew ; Chen, Weiqiang ; Huang, Zhujun ; Shahrjerdi, Davood ; Parashar, Nitika ; Wright, Alexander ; Deshmukh, Rahul ; Manzo-Perez, Miguel ; Jamalzadeh, Moeid ; Udumulla, Thanuka

AbstractThe rise in antibiotic-resistant pathogens, highly infectious viruses, and chronic diseases has prompted the search for rapid and versatile medical tests that can be performed by the patient. An electronic biosensing platform based on field-effect transistors (FETs) is particularly attractive due to sensitivity, fast turn-around, and compatibility with semiconductor manufacturing. However, the lack of methods for pathogen-specific functionalization of individual FETs prevents parallel detection of multiple pathogens. Indeed, so far functionalization of FET based biosensors is achieved by drop casting without any spatial selectivity. Here, we propose a paradigm shift in FET’s biofunctionalization. Specifically, we use thermal scanning probe lithography (tSPL) with a thermochemically sensitive polymer that can be spin-coated on any FET material. We demonstrate that this scalable, CMOS compatible methodology can be used to functionalize individual FETs with different bioreceptors on the same chip, at sub-20 nm resolution, paving the way for massively parallel FET detection of multiple pathogens. Antibody- and aptamer-modified FET sensors are then realized, achieving an ultra-sensitive detection of 5 aM of SARS-CoV-2 spike proteins and 10 human SARS-CoV-2 infectious live virus particles/ml, and selectivity against human influenza A (H1N1) live virus.

100 Deals associated with Virostatics Srl

Login to view more data

100 Translational Medicine associated with Virostatics Srl

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

6

1

Phase 2 Clinical

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DermaVir	HIV Infections More	Phase 2
Varicella-Zoster virus(ViroStatics)	Varicella Zoster Virus Infection More	Preclinical
VS2-370 ( CDK9 )	HIV Infections More	Preclinical
SARS-CoV-2(ViroStatics)	COVID-19 More	Preclinical
CDK6 inhibitors(ViroStatics) ( CDK6 )	Respiratory Distress Syndrome, Acute More	Preclinical